RGRenwei Guo

Renwei Guo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Renwei Guo has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Lixia Bu

    Department of Geratology, Fenyang Hospital of Shanxi Province, Fenyang, China

    2 shared publications
  • Mingfeng Ma

    Department of Cardiovascular Medicine, Fenyang Hospital Affiliated with Shanxi Medical University, Fenyang, Shanxi, China

    2 shared publications
  • Huiwen Wu

    Science and Technology Center, Fenyang College of Shanxi Medical University, Shanxi 032200, PR China

    1 shared publication
  • Liqiang Zheng

    School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    1 shared publication
  • Peigang Zhang

    Department of Cardiothoracic Surgery, Lvliang People’s Hospital, Li Shi, China

    1 shared publication
  • Songhao Tian

    Department of Medical Laboratory Science, Fenyang College of Shanxi Medical University, Fenyang, China

    1 shared publication

Latest Publications

  • Open Access

    Cathepsin D inhibits AGEs-induced phenotypic transformation in vascular smooth muscle cells

    by Xingmin He, Songhao Tian, Lixia Bu, Xinna Zhao, Liqiang Zheng, Peigang Zhang, Renwei Guo, Mingfeng Ma

    This study investigates the role of Cathepsin D (CTSD) in diabetic vascular complications, particularly its impact on the phenotypic transformation of vascular smooth muscle cells (VSMCs) induced by advanced glycation end-products (AGEs), and explores its potential molecular mechanisms. CTSD was overexpressed in VSMCs using lentiviral vectors. Various methods, including CCK-8, immunofluorescence, SA-β-Gal staining, EdU assay, scratch assay, cell cycle analysis, and Western blotting, were employed to assess VSMC viability, proliferation, migration, senescence, and apoptosis. Additionally, transcriptomic and metabolomic analyses were conducted to investigate the molecular mechanisms underlying CTSD overexpression in VSMCs. AGEs treatment significantly inhibited CTSD expression in VSMCs, leading to reduced cell viability, enhanced proliferation and migration, increased senescence, and apoptosis. In contrast, overexpression of CTSD effectively inhibited AGEs-induced VSMCs proliferation, migration, senescence, and apoptosis. Combined transcriptomic and metabolomic analyses suggested that CTSD may affect VSMCs phenotypic transformation by inhibiting the glycolysis pathway. This study highlights the critical role of CTSD in the phenotypic transformation of VSMCs induced by AGEs and provides a new perspective for cardiovascular and cerebrovascular disease treatment. CTSD may emerge as a novel therapeutic target, though its specific molecular mechanisms and clinical application prospects in VSMCs phenotypic transformation require further investigation.